Hetero group launched Favipiravir in India to treat Covid-19 infected patients

Download our All Government Jobs Android app to get updates on your mobile.

29 July 2020 Current Affairs:Hetero group has launched the generic Favipiravir in India under the brand ‘Favivir’. The company received approvals from the Drug Controller General of India (DCGI) to manufacture and market the generic drug. The drug, Favivir, is used to treat mild to moderate COVID-19.

Favivir:
Favivir will improve treatment accessibility to a significant amount of the COVID-19 patient population, which usually sustains mild to moderate symptoms.
The generic favipiravir drug is priced at Rs.59 per tablet. 
The drug is being marketed and distributed by Hetero Healthcare.
The product is made available at all retail medical outlets and hospital pharmacies across India to be sold on prescription.
Favivir is prepared at a world-class formulation facility, which was approved by USFDA and the EU.
Favivir is the second drug developed by Hetero. Earlier, the company launched Covifor, the generic version of Remdesivir injection to be administered intravenously in a hospital to traet severe COVID-19 infection.

source https://naukri.sarkari-exam.in/hetero-group-launched-favipiravir-in-india-to-treat-covid-19-infected-patients/

Download our All Government Jobs Android app to get updates on your mobile.